Physician profile
Deepthi Murthy
NPI 1265476089
$4,125.33
in general payments reported to CMS, 2019-2025
25 companies · $520 in 2025
The $520 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2020: $63.15 · 2021: $461 · 2022: $839 · 2023: $1,025 · 2024: $822 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,367.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $1,406.90 | 2019-2025 | Arikayce, Brinsupri |
| Viiv Healthcare Company | $555.71 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Merck Sharp & Dohme LLC | $289.02 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Gilead Sciences, INC. | $251.24 | 2019-2025 | Veklury |
| Abbvie INC. | $234.53 | 2022-2025 | |
| Shionogi INC | $230.33 | 2022-2025 | Fetroja |
| Takeda Pharmaceuticals U.S.A., INC. | $225.56 | 2022-2023 | Livtencity |
| Paratek Pharmaceuticals, INC. | $143.08 | 2019-2024 | Nuzyra |
| Astellas Pharma US INC | $127.24 | 2021-2024 | Cresemba |
| Janssen Biotech, INC. | $111.16 | 2019-2023 | Symtuza |
| Vbi Vaccine (Delaware) INC. | $76.39 | 2022-2023 | Prehevbrio |
| Melinta Therapeutics, LLC | $70.00 | 2019-2023 | Rezzayo, Vabomere, Orbactiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.33 | 2021-2023 | Xifaxan |
| La Jolla Pharmaceutical Company | $57.51 | 2021-2023 | Xerava |
| Theratechnologies INC. | $57.21 | 2019-2024 | Trogarzo, Egrifta |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $57.18 | 2023 | Hizentra |
| Electromed, INC. | $29.10 | 2021-2022 | |
| Hologic Sales and Service, LLC | $25.24 | 2024 | Aptima, Thinprep 2000 Processor |
| Aimmune Therapeutics, INC. | $24.19 | 2023 | |
| Dynavax Technologies Corporation | $22.19 | 2021 | |
| Ferring Pharmaceuticals INC. | $19.93 | 2025 | Rebyota |
| Allergan, INC. | $14.94 | 2019 | |
| Vyera Pharmaceuticals, LLC | $11.59 | 2019 | |
| Smith+Nephew, INC. | $11.47 | 2019 | |
| Pfizer INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepthi Murthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.